Comparison of three different methods for measurement of tissue platinum level.
We attempted to make a comparison of three methods for tissue platinum; atomic absorption spectrometry (AAS), inductively coupled plasma atomic emission spectrometry (ICP-AES), and inductively coupled plasma mass spectrometry (ICP-MS). The determination limits were 0.05 ng/mL on ICP-MS, 50 ng/mL on ICP-AES, and 200 ng/mL on AAS, and the recovery rates were 97.7 +/- 6.9% on ICP-MS, 69.0 +/- 3.0% on ICP-AES, and 102.4 +/- 4.0% on AAS, respectively. Platinum was detected by ICP-AES and ICP-MS in human vertebrae, but the level was higher by ICP-AES than by ICP-MS. In the mouse kidney treated with cisplatin, platinum was detected by ICP-MS, but not by ICP-AES. As cadmium gives the absorption peak close to platinum, cadmium was measured together with platinum by ICP-AES in the vertebrae. From these, ICP-MS is the most sensitive for measurement at tissue platinum. The sensitivity of ICP-AES looks worse for measuring the tissue platinum, and it is necessary to take care of the contaminant of metals, especially cadmium. AAS is not suitable for measurement of tissue platinum as in the vertebrae and kidneys, because platinum was not detectable by AAS.
Minami
T
T
Faculty of Pharmaceutical Sciences, Kinki University, Osaka, Japan.
Ichii
M
M
Okazaki
Y
Y
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D002104:Cadmium / Q000032:analysis / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000737:chemistry* / Q000378:metabolism; D008159:Lumbar Vertebrae / Q000737:chemistry* / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010984:Platinum / Q000032:analysis* / Q000378:metabolism; D013054:Spectrophotometry, Atomic; D014018:Tissue Distribution
D002104:Cadmium; D010984:Platinum; D002945:Cisplatin